DPP4 and type 2 diabetes mellitus: Moreover, a recent in vivo study showed that MK-0626, a DPP-4 inhibitor, had neutral effects on cortical and trabecular bone in an animal model of type 2 diabetes, and MK-0626 did not alter osteoblast differentiation30.